Fundraising Fox
/Companies
Sign in

Judo Bio

Cambridge, US · Founded 2021 · 34 employees on LinkedIn · 5 known investors

Find your way into Judo Bio

Sign up to see every warm intro you have to Judo Bio

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Judo Bio team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Judo Bio develops oligonucleotide medicines, including ligand-siRNA conjugate drugs, delivered to the kidney for systemic and renal diseases using its STRIKE (Selectively Targeting RNA Into KidnEy) platform. The company applies RNA-based therapeutics that harness a natural endogenous mechanism for receptor-mediated uptake by specific kidney cell types to silence disease-modifying genes.

BiotechHealthtech

Founders & leadership

Judo Bio was founded in 2021 by Andrew Fraley and Alfica Sehgal.

AFAndrew Fraley
Andrew FraleyJudo Bio Co-FounderCo-founder and Chief Technology Officer of Judo Bio, Andrew Fraley previously co-founded Korro Bio, a company developing RNA editing therapeutics, and has held leadership roles advising biotech startups in genetic medicine and RNA therapeutics.
ASAlfica Sehgal
Alfica SehgalFounder
OCOMMER CHOHAN
OMMER CHOHANExecutiveCFO at Atlas Venture
JJ
JAMES JEFFREY GOATERExecutive
SRSimon Read
Simon ReadExecutive Chair and Acting CEOSimon Read is Executive Chairman of Judo Bio, which develops oligonucleotide medicines for systemic and renal diseases using its STRIKE platform. He previously founded and served as CEO of Mariana Oncology (acquired by Novartis in 2024) and held the Chief Scientific Officer role at Ra Pharma (acquired by UCB Pharma in 2020), bringing over 25 years of R&D experience in drug development across GlaxoSmithKline, AstraZeneca, and Roche/Genentech.
WHWilliam Ho
William Ho
CP
CHELSEA PLACE JOHNSONNamed on SEC filingPrincipal at Atlas Venture
SR
Steven Robinette, PhDJudo Bio Founder; Venture Partner, Atlas Venture

Board

KBKEVIN BITTERMAN
KEVIN BITTERMANBoard of DirectorsPartner at Atlas Venture
SBSAM BJORK
SAM BJORKBoard directorPartner at Digitalis Ventures
HTHUI TIAN
HUI TIANBoard directorPartner at The Column Group
GGGEORGE GOLUMBESKI
GEORGE GOLUMBESKIBoard directorPartner at Droia Ventures

Investors · 5

Digitalis Ventures✓ confirmed by Judo BioNew York · $100K – $10M

How we know: Digitalis Ventures's portfolio page · the company's own site · a partner's Signal profile · funding news · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

Droia Ventures✓ confirmed by Judo BioLuxembourg · $540K

How we know: the company's own site · Droia Ventures's portfolio page · funding news · open dataset · 5k.vc investor directory · Not right? Tell us

The Column Group✓ confirmed by Judo BioSan Francisco · $30M

How we know: The Column Group's portfolio page · the company's own site · a partner's Signal profile · funding news · the VCSheet dataset · Not right? Tell us

YK BioventuresreportedBurlingame

How we know: funding news · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$55M disclosed across 3 rounds · 2022–2024

▶$25MraisedAug 2024 · 21 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • GEORGE GOLUMBESKIDirector
  • OMMER CHOHANExecutive Officer
  • ANKIT MAHADEVIADirector
  • JAMES JEFFREY GOATERExecutive Officer, Director
  • KEVIN BITTERMANExecutive Officer, Director
  • SAM BJORKDirector
Amount sold
$25M
First sale
Jul 2024
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5MraisedJun 2024 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • OMMER CHOHANExecutive Officer
  • CHELSEA PLACE JOHNSONDirector
  • KEVIN BITTERMANExecutive Officer, Director
  • JAMES JEFFREY GOATERExecutive Officer, Director
  • ANKIT MAHADEVIADirector
  • HUI TIANDirector
Offering amount
$5M
Amount sold
$5M
First sale
May 2024
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$25MraisedNov 2023 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • JAMES JEFFREY GOATERDirector
  • CHELSEA PLACE JOHNSONDirector
  • ANKIT MAHADEVIADirector
  • KEVIN BITTERMANExecutive Officer, Director
  • HUI TIANDirector
  • OMMER CHOHANExecutive Officer
Amount sold
$25M
First sale
Nov 2022
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

5 people who came through Judo Bio went on to found or lead other companies.

Ankit MahadeviaMember Board of DirectorsFounded Spero Therapeutics +1Simon ReadExecutive Chair and Acting CEOFounded Mariana Oncology +1Kevin BittermanExecutive Officer, DirectorFounded Editas MedicineJeff GoaterExecutive ChairFounded Atavistik BioAndrew FraleyJudo Bio Co-FounderFounded Korro Bio

Related companies · 2

Sudo BioSudo Biosciences develops small molecule therapeutics for neurological and immune-mediated inflammatory conditions. The company focuses on drug development and translational biology to address unmet medical needs.
Ditto BiosciencesDitto Bio uses AI to identify protein candidates from parasites and pathogens for treating autoimmune diseases. The company mines natural compounds from viruses, ticks, and worms whose immune-modulating properties have evolved over millions of years.

Companies working in the same space as Judo Bio.

In the news

Judo Bio Raises $100M in Seed and Series A Financingfinsmes.com · Oct 2024

Frequently asked questions

What does Judo Bio do?
Judo Bio develops oligonucleotide medicines, including ligand-siRNA conjugate drugs, delivered to the kidney for systemic and renal diseases using its STRIKE (Selectively Targeting RNA Into KidnEy) platform. The company applies RNA-based therapeutics that harness a natural endogenous mechanism for receptor-mediated uptake by specific kidney cell types to silence disease-modifying genes.
Who founded Judo Bio?
Judo Bio was founded by Andrew Fraley, Alfica Sehgal in 2021.
Who are Judo Bio's investors?
Judo Bio's investors include Atlas Venture, Digitalis Ventures, Droia Ventures, The Column Group, YK Bioventures.
How much funding has Judo Bio raised?
Judo Bio has disclosed $55M raised across 3 rounds.
Where is Judo Bio headquartered?
Judo Bio is headquartered in Cambridge, US.